본문 바로가기 주메뉴 바로가기
국회도서관 홈으로 정보검색 소장정보 검색

결과 내 검색

동의어 포함

초록보기

Objective: Lamivudine (LAM) is the first nucleoside analog approved for chronic hepatitis B (CHB) patients, but acquired mutation of the reverse transcriptase of the virus during long-term therapy is limiting its use. Adeforvir dipivoxil (ADV) add-on therapy with ongoing LAM use has been a standard therapy for LAM resistance. The aim of this study was to explore the predictive factors associated with delayed virologic response at 12 months in patients who could not achieved initial virologic response (IVR) of add-on therapy. Methods: One hundred and ninety three LAM-resistant CHB patients who had been on ADV add-on therapy with LAM and were not achieved IVR at 6 months were enrolled. They were classified into delayed viral response (DVR) group and non-DVR group, according to delayed viral response (VR) at 12 months of add-on therapy. Clinical factors predicting delayed VR at 12 months of addon therapy were evaluated. Results: DVR rate was 20.7% (n=40) at 12 months after the add-on treatment. Female (adjusted odds ratio, 3.463; P=0.002), lower hepatitis B virus (HBV) DNA at baseline (<7.0 log copies/mL/≥7.0 log copies/mL; adjusted odds ratio, 0.369; P=0.012), and negative HBeAg at baseline (adjusted odds ratio, 0.332; P=0.034) were significant independent factors predicting DVR after 12 months of treatment. Conclusion: In LAM-resistant CHB patients with ADV add-on therapy, although there was no IVR after 6 months treatment, we could consider maintenance of treatment if patient is female, lower HBV DNA state, or HBeAg negative state at the time of starting add-on therapy.

권호기사

권호기사 목록 테이블로 기사명, 저자명, 페이지, 원문, 기사목차 순으로 되어있습니다.
기사명 저자명 페이지 원문 목차
Awake during General Anesthesia with BispectralIndex Value of 35 이세진, 김순임, 옥시영, 김상호, 박선영, 김문규, 전혜림, 서혜진, 조아나, 박세광 pp.29-30

소아와 청소년기에 발생한 하시모토 갑상샘염과 Hashitoxicosis의 임상적 경과에 대한 연구 이영임, 박재영, 신영림 pp.17-22

Bortezomib Induced Tumor Lysis Syndrome in Multiple Myeloma 유시내, 류성우, 김경하, 김세형, 이남수, 박성규, 원종호 pp.31-33

라미부딘 내성 만성 B형 간염 환자에서 아데포비어 병합치료의 지연 바이러스 반응 예측인자 백애린, 김대용, 김영석, 김상균, 김정현, 김태진, 이윤나, 이세환, 정승원, 장재영, 김홍수, 김부성, 김민석 pp.10-16

Endometriosis of the Appendix 이진형, 박내경 pp.23-25

Intermittent Pneumatic Compression Device 사용으로 인한 수술 후 총비골신경 전혜림, 고은효, 서혜진, 박선영, 이세진, 옥시영 pp.49-50

벨마비 후 촉각자극과 씹기에 의해 유발되는 반대측 삼차신경통 김승주, 박덕수, 정두신, 양광익, 박형국, 오형근 pp.42-44

Dislodgement of Two Stents in One Patient during Percutaneous Coronary Intervention 김혜진, 안지현, 김태훈, 김도희 pp.26-28

제2형 당뇨병 환자에서 비케톤성 고혈당의 합병증으로 발생한 편측성 무도병 김지혜, 박형규 pp.34-37

극심한 급성빈혈에 의한 사망 증례와 단독 사망 예측인자 : 혈색소 농도 2g/dL 박선영, 강성현, 박상훈, 전혜림, 김문규, 이세진 pp.45-48

호흡기 검체에서 결핵균 검출을 위한 Cobas TaqMan MTB의 성능분석 최영진 pp.1-5

정형외과 수술을 시행 받은 사립체 근병증 환자의 마취관리 1예 구본성, 김민재, 이미순 pp.38-41

대상포진으로 인한 배뇨곤란이 발생한 여성 환자 10예에서 Famciclovir를 이용한 치료 경험 윤종현 pp.6-9

참고문헌 (25건) : 자료제공( 네이버학술정보 )

참고문헌 목록에 대한 테이블로 번호, 참고문헌, 국회도서관 소장유무로 구성되어 있습니다.
번호 참고문헌 국회도서관 소장유무
1 Prevalence and Clinical Correlates of YMDD Variants during Lamivudine Therapy for Patients with Chronic Hepatitis B 네이버 미소장
2 Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. 네이버 미소장
3 Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, et al. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. J Gastroenterol Hepatol 2010;25:1374-80. 미소장
4 Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. 네이버 미소장
5 Chung GE, Kim W, Lee KL, Hwang SY, Lee JH, Kim HY, et al. Add-on adefovir is superior to a switch to entecavir as rescue therapy for Lamivudine- resistant chronic hepatitis B. Dig Dis Sci 2011;56:2130-6. 미소장
6 Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. 네이버 미소장
7 Treatment of lamivudine-resistant chronic hepatitis B infection: a multicenter retrospective study. 네이버 미소장
8 Yim HJ, Seo YS, Yoon EL, Kim CW, Lee CD, Park SH, et al. Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial. Liver Int 2013;33:244-54. 미소장
9 KASL Clinical Practice Guidelines: Management of chronic hepatitis B 네이버 미소장
10 Management options for lamivudine‐resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir 네이버 미소장
11 Viral response at 6 months is associated with treatment outcome of adefovir add‐on therapy for lamivudine‐resistance 네이버 미소장
12 Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir. 네이버 미소장
13 Long-term safety of lamivudine treatment in patients with chronic hepatitis B 네이버 미소장
14 Identification and characterization of mutations in hepatitis B virus resistant to lamivudine 네이버 미소장
15 [502] ADEFOVIR AND LAMIVUDINE COMBINATION THERAPY IS SUPERIOR TO ADEFOVIR MONOTHERAPY FOR LAMIVUDINE-RESISTANT PATIENTS WITH HBeAg-NEGATIVE CHRONIC HEPATITIS B 네이버 미소장
16 Long-term outcomes of add-on adefovir dipivoxil therapy to ongoing lamivudine in patients with lamivudine-resistant chronic hepatitis B. 네이버 미소장
17 High efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B 소장
18 Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy. 네이버 미소장
19 Comparison of rescue strategies in lamivudine-resistant patients with chronic hepatitis B 네이버 미소장
20 The efficacy of adefovir plus entecavir combination therapy in patients with chronic hepatitis B refractory to both lamivudine and adefovir. 네이버 미소장
21 Original Article : A Low Viral Load Predicts a Higher Initial Virologic Response to Adefovir in Patients with Lamivudine-Resistant Chronic Hepatitis B 네이버 미소장
22 The influence of YMDD mutation patterns on clinical outcomes in patients with adefovir add‐on lamivudine combination treatment 네이버 미소장
23 You H, Wu X, Ou X, Ma H, Wang Q, Liu T, et al. Two patterns of alanine aminotransferase increase to predict long-term viral response in chronic hepatitis B patients: virus- or host-induced? Antivir Ther 2011;16:299- 307. 미소장
24 Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients. 네이버 미소장
25 Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures. 네이버 미소장